BCM
MYGN icon

Bridgeway Capital Management’s Myriad Genetics MYGN Stock Holding History

Bridgeway Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-32,000
Closed -$614K – 1451
2017
Q1 		$614K Buy
32,000
+5,000
+19% +$88.6K 0.01% 992
2016
Q4 		$450K Hold
27,000
– – 0.01% 1119
2016
Q3 		$556K Buy
+27,000
New +$685K 0.01% 1043

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Bridgeway Capital Management's MYGN Position: Q2 2017 in Review

Bridgeway Capital Management sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 32,000 shares — an estimated $614K sold.

Bridgeway Capital Management first reported a position in MYGN in Q3 2016 and held it in 3 quarters. The position peaked at $614K in Q1 2017. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • Bridgeway Capital Management reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • Bridgeway Capital Management sold 32,000 Myriad Genetics shares in Q2 2017, an estimated $614K.
  • Bridgeway Capital Management first reported a position in Myriad Genetics in Q3 2016 and held it in 3 quarters.
  • Bridgeway Capital Management's Myriad Genetics position peaked at $614K in Q1 2017.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Bridgeway Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.